|
WO2021076908A1
|
|
Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
|
|
WO2021022044A1
|
|
Depletion regimes for engineered t-cell or nk-cell therapy
|
|
US2020369767A1
|
|
Regimes for co-administration of immunotherapeutic agents against c-kit and cd47
|
|
WO2020198353A1
|
|
Multispecific agents for treatment of cancer
|
|
WO2020112870A1
|
|
Genetically modified hspcs resistant to ablation regime
|
|
US2020165337A1
|
|
Humanized antibodies against c-kit
|
|
US2019248915A1
|
|
Anti-CD47 Agent-Based Treatment of CD20-Positive Cancer
|
|
WO2019079548A1
|
|
Anti-cd47 agent-based ovarian cancer therapy
|
|
CA3078430A1
|
|
Treatment of ovarian cancer with anti-cd47 and anti-pd-l1
|
|
SG11202000658PA
|
|
Anti-sirp-alpha antibodies and related methods
|
|
AU2018290248A1
|
|
Dosing parameters for CD47 targeting therapies to hematologic malignancies
|
